Table 5.

Proportion of patients with renal impairment by baseline characteristics: percentage decrease in renal function below the 25th percentile eGFR (MDRD)

^aShaded categories were not considered for tests

^bAt the start of EVR treatment

^cAngiotensin II receptor antagonists, angiotensin-converting enzyme inhibitors, treatment drugs for dyslipidemia, and treatment drugs for diabetes mellitus including insulin

^dPatients with CNI dose reduction were defined as those in whom the dosage of CNIs was reduced by ≥ 30% relative to the dose at the start of treatment at ≥ 2 time points out of all assessment points

AE adverse event, CI confidence interval, CNI calcineurin inhibitor, eGFR estimated glomerular filtration rate, EVR everolimus, HLA human leukocyte antigen, MDRD modification of diet in renal disease, MMF mycophenolate mofetil, OR odds ratio, Tx transplantation, UPCR urinary protein/creatinine ratio